Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma.
T cells
fibroblast activation protein
fibroblasts
immunosuppression
low‐grade serous ovarian carcinoma
macrophages
multiplex IHC
regulatory T cells
serous borderline ovarian tumours
tumour microenvironment
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
31 Jul 2024
31 Jul 2024
Historique:
revised:
06
05
2024
received:
10
01
2024
accepted:
22
06
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
aheadofprint
Résumé
Low-grade serous ovarian carcinoma (LGSC) is a rare and lethal subtype of ovarian cancer. LGSC is pathologically, biologically, and clinically distinct from the more common high-grade serous ovarian carcinoma (HGSC). LGSC arises from serous borderline ovarian tumours (SBTs). The mechanism of transformation for SBTs to LGSC remains poorly understood. To better understand the biology of LGSC, we performed whole proteome profiling of formalin-fixed, paraffin-embedded tissue blocks of LGSC (n = 11), HGSC (n = 19), and SBTs (n = 26). We identified that the whole proteome is able to distinguish between histotypes of the ovarian epithelial tumours. Proteins associated with the tumour microenvironment were differentially expressed between LGSC and SBTs. Fibroblast activation protein (FAP), a protein expressed in cancer-associated fibroblasts, is the most differentially abundant protein in LGSC compared with SBT. Multiplex immunohistochemistry (IHC) for immune markers (CD20, CD79a, CD3, CD8, and CD68) was performed to determine the presence of B cells, T cells, and macrophages. The LGSC FAP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : U.S. Department of Defense
ID : OC200231
Organisme : BC Cancer Foundation
Organisme : VGH and UBC Hospital Foundations
Organisme : Chew Wei Memorial Professorship
Organisme : Canada Research Chairs Program
Informations de copyright
© 2024 The Pathological Society of Great Britain and Ireland.
Références
Gourley C, Farley J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low‐grade serous carcinomas. Int J Gynecol Cancer 2014; 24: S9–S13.
Plaxe SC. Epidemiology of low‐grade serous ovarian cancer. Am J Obstet Gynecol 2008; 198: 459.e1–459.e9.
Hunter SM, Anglesio MS, Ryland GL, et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 2015; 6: 37663–37677.
Babaier A, Mal H, Alselwi W, et al. Low‐grade serous carcinoma of the ovary: the current status. Diagnostics (Basel) 2022; 12: 458.
Hogg R, Scurry J, Kim S‐N, et al. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Gynecol Oncol 2007; 106: 44–51.
May T, Virtanen C, Sharma M, et al. Low malignant potential tumors with micropapillary features are molecularly similar to low‐grade serous carcinoma of the ovary. Gynecol Oncol 2010; 117: 9–17.
Manning‐Geist BL, Kahn RM, Nemirovsky D, et al. Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies. Cancer 2023; 129: 2004–2012.
Hollis RL, Thomson JP, vanBaal J, et al. Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma. Sci Rep 2023; 13: 7681.
Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low‐grade serous carcinoma of the ovary or peritoneum: an open‐label, single‐arm, phase 2 study. Lancet Oncol 2013; 14: 134–140.
Shrestha R, Fernandez ML, Dawson A, et al. Multiomics characterization of low‐grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability. Cancer Res 2021; 81: 1681–1694.
Wong K‐K, Bateman NW, Ng CW, et al. Integrated multi‐omic analysis of low‐grade ovarian serous carcinoma collected from short and long‐term survivors. J Transl Med 2022; 20: 606.
Banerjee SN, Ring KL, Nieuwenhuysen EV, et al. Initial efficacy and safety results from ENGOT‐Ov60/GOG‐3052/RAMP 201: a phase 2 study of avutometinib (VS‐6766) ± defactinib in recurrent low‐grade serous ovarian cancer (LGSOC). J Clin Oncol 2023; 41: 5515.
Bonome T, Lee J‐Y, Park D‐C, et al. Expression profiling of serous low malignant potential, low‐grade, and high‐grade tumors of the ovary. Cancer Res 2005; 65: 10602–10612.
Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low‐ and high‐grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218–224.
Vineyard MA, Daniels MS, Urbauer DL, et al. Is low‐grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol 2011; 120: 229–232.
Brandt S, Samartzis EP, Zimmermann A‐K, et al. Lack of MRE11‐RAD50‐NBS1 (MRN) complex detection occurs frequently in low‐grade epithelial ovarian cancer. BMC Cancer 2017; 17: 44.
Cheasley D, Nigam A, Zethoven M, et al. Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol 2021; 253: 41–54.
Zeng L, Wang Q, Gu C, et al. Asparagine synthetase and filamin A have different roles in ovarian cancer. Front Oncol 2019; 9: 1072.
Pejovic T, Abate P‐V, Ma H, et al. Single‐cell proteomics analysis of recurrent low‐grade serous ovarian carcinoma and associated brain metastases. Front Oncol 2022; 12: 903806.
Magdeldin S, Yamamoto T. Toward deciphering proteomes of formalin‐fixed paraffin‐embedded (FFPE) tissues. Proteomics 2012; 12: 1045–1058.
Asleh K, Negri GL, Miko SES, et al. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat Commun 2022; 13: 896.
Hughes CS, McConechy MK, Cochrane DR, et al. Quantitative profiling of single formalin fixed tumour sections: proteomics for translational research. Sci Rep 2016; 6: 34949.
Henry LR, Lee H‐O, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13: 1736–1741.
Zhu Y, Orre LM, Tran YZ, et al. DEqMS: a method for accurate variance estimation in differential protein expression analysis. Mol Cell Proteomics 2020; 19: 1047–1057.
Matusiak M, Hickey J, Luca B, et al. A spatial map of human macrophage niches reveals context‐dependent macrophage functions in colon and breast cancer. Res Sq 2023: rs.3.rs‐2393443. Not peer reviewed.
Rettig WJ, Garin‐Chesa P, Beresford HR, et al. Cell‐surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A 1988; 85: 3110–3114.
Garin‐Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990; 87: 7235–7239.
Costa A, Kieffer Y, Scholer‐Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 2018; 33: 463–479.e10.
Givel A‐M, Kieffer Y, Scholer‐Dahirel A, et al. miR200‐regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun 2018; 9: 1056.
Kieffer Y, Hocine HR, Gentric G, et al. Single‐cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov 2020; 10: 1330–1351.
Hussain A, Voisin V, Poon S, et al. Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. J Exp Med 2020; 217: e20191094.
Köbel M, Kang E, Lee S, et al. Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma. Histopathology 2024; 84: 1095–1110.
Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804–811.
Chen X, Du Y, Lin X, et al. CD4+CD25+ regulatory T cells in tumor immunity. Int Immunopharmacol 2016; 34: 244–249.
Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci 2019; 110: 2080–2089.
Miyasato Y, Shiota T, Ohnishi K, et al. High density of CD204‐positive macrophages predicts worse clinical prognosis in patients with breast cancer. Cancer Sci 2017; 108: 1693–1700.
He Y, Zhou S, Deng F, et al. Clinical and transcriptional signatures of human CD204 reveal an applicable marker for the protumor phenotype of tumor‐associated macrophages in breast cancer. Aging (Albany NY) 2019; 11: 10883–10901.
Sica A, Schioppa T, Mantovani A, et al. Tumour‐associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti‐cancer therapy. Eur J Cancer 2006; 42: 717–727.
Pathria P, Louis TL, Varner JA. Targeting tumor‐associated macrophages in cancer. Trends Immunol 2019; 40: 310–327.
Ingman WV, Wyckoff J, Gouon‐Evans V, et al. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn 2006; 235: 3222–3229.
Moussai D, Mitsui H, Pettersen JS, et al. The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage‐derived VEGF‐C. J Invest Dermatol 2011; 131: 229–236.
Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour‐associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012; 167: 195–205.
Ciucci A, Zannoni GF, Buttarelli M, et al. Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment. Oncotarget 2016; 7: 68033–68043.
Mazur A, Holthoff E, Vadali S, et al. Cleavage of type I collagen by fibroblast activation protein‐α enhances class A scavenger receptor mediated macrophage adhesion. PLoS One 2016; 11: e0150287.
Liao D, Luo Y, Markowitz D, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009; 4: e7965.
Hou CM, Qu XM, Zhang J, et al. Fibroblast activation proteins‐α suppress tumor immunity by regulating T cells and tumor‐associated macrophages. Exp Mol Pathol 2018; 104: 29–37.
Seager RJ, Hajal C, Spill F, et al. Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. Converg Sci Phys Oncol 2017; 3: 034002.
Zalatnai A. Molecular aspects of stromal–parenchymal interactions in malignant neoplasms. Curr Mol Med 2006; 6: 685–693.
Martinez M, Kim S, St Jean N, et al. Addition of anti‐TIM3 or anti‐TIGIT antibodies to anti‐PD1 blockade augments human T cell adoptive cell transfer. Oncoimmunology 2021; 10: 1873607.
Nanki T, Lipsky PE. Cutting edge: stromal cell‐derived factor‐1 is a costimulator for CD4+ T cell activation. J Immunol 2000; 164: 5010–5014.
Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP‐expressing carcinoma‐associated fibroblasts synergizes with anti‐PD‐L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013; 110: 20212–20217.
Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210: 1125–1135.
Kakarla S, Chow KK, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013; 21: 1611–1620.
Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein‐specific re‐directed T cells. J Transl Med 2013; 11: 187.
Mori Y, Dendl K, Cardinale J, et al. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology 2023; 306: e220749.
Gershenson DM, Silva EG, Tortolero‐Luna G, et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 1998; 83: 2157–2163.
Gershenson DM, Silva EG, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998; 82: 1096–1103.
Silva E, Vang R, Kurman R, et al. Invasive implants of serous borderline ovarian neoplasms – a multiinstitutional study. Mod Pathol 2006; 19: 197A.
Perez‐Riverol Y, Bai J, Bandla C, et al. The PRIDE database resources in 2022: a hub for mass spectrometry‐based proteomics evidences. Nucleic Acids Res 2021; 50: D543–D552.